What’s the Skinny on Skinny Labeling?

Join Polsinelli for a webinar that will discuss case law developments over the past year, strategic considerations for induced infringement claims in patent litigation in the pharma and biologics space, and how to handle product label amendments at FDA.

Recent case law has shed light on how courts are evaluating induced infringement claims involving method of use patents, along with pitfalls that generic and biosimilar companies need to be mindful of and avoid. Additionally, for the first time last year, an appellate court affirmed FDA allowing a generic company to carve out an indication by adding language to a label, which some have dubbed “chubby labeling.” This presentation will discuss these developments and the strategic considerations that companies need to be mindful of in light of the changing case law.

Agenda

• Recent case law involving induced infringement claims in the pharmaceutical industry
• Litigation strategies for addressing induced infringement
• Skinny and Chubby Labels: the latest on FDA’s view and litigation involving approval of label carveouts

CLE Credit Pending